Each year, it is estimated that 178,000 newborns and 773,000 children die from pneumonia, making it the leading global cause of death in children under five.1 Increasingly, the major pneumonia burden is in the first 2 years of life, with the problem being particularly challenging in low-resource settings such as sub-Saharan Africa.2,3
It is time for action in eliminating pneumonia. Today Masimo and its partners in the fight against pneumonia are debuting a documentary entitled United for Oxygen, examining the problem, available at this link, and ask for your assistance in spreading the word across the world.
Along with more than 30 other organizations, including UNICEF, Save the Children, The Newborn Foundation, The Bill & Melinda Gates Foundation, The Clinton Health Access Initiative, GSK, and Philips, Masimo is a founding member of the “Every Breath Counts Coalition,” dedicated to eliminating all pneumonia-related deaths. Each member of the coalition brings unique expertise to the problem, with some working on pneumococcal vaccine coverage, some on access to medical oxygen, others on education, and, in Masimo’s case, the use of SET® pulse oximetry, the most accurate and reliable pulse oximetry in the world;4 pulse oximetry is often included in relevant pneumonia clinical screening protocols. As part of a grant from The Bill & Melinda Gates Foundation, Masimo has developed Rad-G™, a low-cost pulse oximeter that can be used as part of pneumonia screening, amongst other applications.
Joe Kiani, Founder and CEO of Masimo, said, “Eliminating pneumonia will take everyone’s unified efforts. Together we can bend the curve and eliminate preventable childhood deaths from pneumonia, so no child has to fight to breathe. How can you help? Join the ‘Every Breath Counts Coalition.’”
Rad-G is currently not available for sale in the United States, Canada, or the E.U.
@MasimoInnovates | #Masimo | #EveryBreathCounts | #United4Oxygen | #StopPneumonia | #NewbornFoundation | #GobeeGroup | #GatesFoundation
1. Miles, Carolyn. Partnering to Fight Pneumonia, The ‘Forgotten Killer’
of Children. Huffington Post. 31 October 2017. https://www.huffingtonpost.com/entry/59f8d6d6e4b0b7f0915f6271.
2. Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhea. Lancet 2013; 381: 1405–16.
3. Green and Kolberg. Neonatal pneumonia in sub-Saharan Africa, Pneumonia (2016) 8:3 DOI 10.1186/s41479-016-0003-0
4. Published clinical studies on Masimo SET® pulse oximetry can be found at http://www.masimo.com/home/clinical-evidence/masimo-set-pulse-oximetry/.
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 17 of the top 20 hospitals listed in the 2017-18 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.
3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
6. Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SET® and Rad-G™ These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SET® and Rad-G, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.